1,25-dihydroxyvitamin D(3) and PI3K/AKT Inhibitors Synergistically Inhibit Growth and Induce Senescence in Prostate Cancer Cells

Overview

Journal Prostate

Date 2010 Jun 29

PMID 20583132

Citations 25

Authors

Linara S Axanova

Yong Q Chen

Thomas McCoy

Guangchao Sui

Scott D Cramer

Affiliations

Soon will be listed here.

Abstract

Background: 1-Alpha, 25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) inhibits proliferation of multiple cancer cell types including prostate cells and upregulates p21 and/or p27, while loss of Pten and PI3K/AKT activation stimulates survival and downregulates p21 and p27. We hypothesized that inhibition of the PI3K/AKT pathway synergizes with the antiproliferative signaling of 1,25(OH)(2)D(3).

Methods: Viability, cell cycle and senescence of cells were evaluated upon combinational treatment with 1,25(OH)(2)D(3) and pharmacological PI3K/AKT inhibitors.

Results: Pharmacological inhibitors of PI3K or Akt and 1,25(OH)(2)D(3) synergistically inhibited growth of DU145, LNCaP, primary human prostate cancer cell strains and Pten null mouse prostatic epithelial cells (MPEC). The inhibitors used included API-2 (Triciribine) and GSK690693 which are currently in clinical trials for treatment of cancer. A novel mechanism for antiproliferative effects of 1,25(OH)(2)D(3) in prostate cells, induction of senescence, was discovered. Combination of 1,25(OH)(2)D(3) and AKT inhibitor cooperated to induce G(1) arrest, senescence, and p21 levels in prostate cancer cells. As AKT is commonly activated by PTEN loss, we evaluated the role of Pten in responsiveness to 1,25(OH)(2)D(3) using shRNA knockdown and by in vitro knockout of Pten. MPEC that lost Pten expression remained sensitive to the antiproliferative action of 1,25(OH)(2)D(3), and showed higher degree of synergism between AKT inhibitor and 1,25(OH)(2)D(3) compared to Pten-expressing counterparts.

Conclusions: These findings provide the rationale for the development of therapies utilizing 1,25(OH)(2)D(3) or its analogs combined with inhibition of PI3K/AKT for the treatment of prostate cancer.

Citing Articles

Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting.

Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X Front Pharmacol. 2025; 16:1516583.

PMID: 40041495 PMC: 11877449. DOI: 10.3389/fphar.2025.1516583.

Targeting PI3K/Akt in Cerebral Ischemia Reperfusion Injury Alleviation: From Signaling Networks to Targeted Therapy.

Zheng T, Jiang T, Ma H, Zhu Y, Wang M Mol Neurobiol. 2024; 61(10):7930-7949.

PMID: 38441860 DOI: 10.1007/s12035-024-04039-1.

Lactic acid promotes nucleus pulposus cell senescence and corresponding intervertebral disc degeneration via interacting with Akt.

Zhang Y, Liu L, Qi Y, Lou J, Chen Y, Liu C Cell Mol Life Sci. 2024; 81(1):24.

PMID: 38212432 PMC: 11071984. DOI: 10.1007/s00018-023-05094-y.

Vitamin D and Hypoxia: Points of Interplay in Cancer.

Gkotinakou I, Mylonis I, Tsakalof A Cancers (Basel). 2022; 14(7).

PMID: 35406562 PMC: 8997790. DOI: 10.3390/cancers14071791.

Unlocking the Mechanisms of Cutaneous Adverse Drug Reactions: Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway by EGFR Inhibitors Triggers Keratinocyte Differentiation and Polarization of Epidermal Immune Responses.

Ondet T, Roux P, Monshouwer M, Stamatas G JID Innov. 2021; 1(2):100009.

PMID: 34909713 PMC: 8659385. DOI: 10.1016/j.xjidi.2021.100009.

References

Li L, Ittmann M, Ayala G, Tsai M, Amato R, Wheeler T . The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18. DOI: 10.1038/sj.pcan.4500776. View

Sansal I, Sellers W . The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004; 22(14):2954-63. DOI: 10.1200/JCO.2004.02.141. View

Beer T, Eilers K, Garzotto M, Egorin M, Lowe B, Henner W . Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2002; 21(1):123-8. DOI: 10.1200/jco.2003.05.117. View

Getzenberg R, Light B, Lapco P, Konety B, Nangia A, Acierno J . Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 1998; 50(6):999-1006. DOI: 10.1016/S0090-4295(97)00408-1. View

Ahonen M, Tenkanen L, Teppo L, Hakama M, Tuohimaa P . Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control. 2000; 11(9):847-52. DOI: 10.1023/a:1008923802001. View

Campisi J, dAdda di Fagagna F . Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8(9):729-40. DOI: 10.1038/nrm2233. View

Deng Z, Wan M, Sui G . PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger. Mol Cell Biol. 2007; 27(10):3780-92. PMC: 1899983. DOI: 10.1128/MCB.01761-06. View

Andreu E, Lledo E, Poch E, Ivorra C, Albero M, Martinez-Climent J . BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 2005; 65(8):3264-72. DOI: 10.1158/0008-5472.CAN-04-1357. View

Dimri G, Lee X, Basile G, Acosta M, Scott G, Roskelley C . A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995; 92(20):9363-7. PMC: 40985. DOI: 10.1073/pnas.92.20.9363. View

10.

Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H . Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis. 2002; 32(2):148-9. DOI: 10.1002/gene.10036. View

11.

Peehl D, Skowronski R, Leung G, Wong S, Stamey T, Feldman D . Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994; 54(3):805-10. View

12.

Vigneron A, Roninson I, Gamelin E, Coqueret O . Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res. 2005; 65(19):8927-35. DOI: 10.1158/0008-5472.CAN-05-0461. View

13.

Barclay W, Cramer S . Culture of mouse prostatic epithelial cells from genetically engineered mice. Prostate. 2004; 63(3):291-8. DOI: 10.1002/pros.20193. View

14.

Li D, Sun H . PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A. 1998; 95(26):15406-11. PMC: 28055. DOI: 10.1073/pnas.95.26.15406. View

15.

Berquin I, Min Y, Wu R, Wu J, Perry D, Cline J . Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest. 2007; 117(7):1866-75. PMC: 1890998. DOI: 10.1172/JCI31494. View

16.

Zhuang S, Schwartz G, Cameron D, Burnstein K . Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol. 1997; 126(1):83-90. DOI: 10.1016/s0303-7207(96)03974-3. View

17.

Ahmed S, Johnson C, Rueger R, Trump D . Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol. 2002; 168(2):756-61. View

18.

Michaloglou C, Vredeveld L, Soengas M, Denoyelle C, Kuilman T, van der Horst C . BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436(7051):720-4. DOI: 10.1038/nature03890. View

19.

Blutt S, Weigel N . Vitamin D and prostate cancer. Proc Soc Exp Biol Med. 1999; 221(2):89-98. DOI: 10.1046/j.1525-1373.1999.d01-60.x. View

20.

Schwartz G, Hulka B . Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990; 10(5A):1307-11. View